Acorda’s Cohen Says Sequestration Delaying New Drugs (Audio)

Ron Cohen, M.D., chief executive officer of Acorda Therapeutics Inc. (ACOR), says sequestration is cutting drug research and delaying new medicines from coming to market. Cohen talks with Bloomberg's Tom Keene and Sara Eisen on Bloomberg Radio's "Bloomberg Surveillance."

(Source: Bloomberg)

Running time 04:44

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.